Visacor

Land: Neuseeland

Sprache: Englisch

Quelle: Medsafe (Medicines Safety Authority)

Wirkstoff:

Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin;  ;  ;  

Verfügbar ab:

AstraZeneca Limited

INN (Internationale Bezeichnung):

Rosuvastatin calcium 5.2 mg (= 5 mg rosuvastatin)

Dosierung:

5 mg

Darreichungsform:

Film coated tablet

Zusammensetzung:

Active: Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin       Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Yellow Iron oxide yellow as Opadry Yellow Lactose monohydrate as Opadry Yellow   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Yellow Triacetin as Opadry Yellow

Einheiten im Paket:

Blister pack, Al/Al foil, 7 tablets

Klasse:

Prescription

Verschreibungstyp:

Prescription

Hergestellt von:

Lonza AG

Anwendungsgebiete:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Produktbesonderheiten:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 7 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Berechtigungsdatum:

2009-07-31